APA

Badrising S., van der Noort V., van Oort I. M., van den Berg H. P., Los M., Hamberg P., Coenen J. L., van den Eertwegh A. J. M., de Jong I. J., Kerver E. D., van Tinteren H. & Bergman A. M. (20140710). Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. : Cancer.

Chicago

Badrising Sushil, van der Noort Vincent, van Oort Inge M, van den Berg H Pieter, Los Maartje, Hamberg Paul, Coenen Jules L, van den Eertwegh Alfons J M, de Jong Igle J, Kerver Emile D, van Tinteren Harm and Bergman Andries M. 20140710. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. : Cancer.

Harvard

Badrising S., van der Noort V., van Oort I. M., van den Berg H. P., Los M., Hamberg P., Coenen J. L., van den Eertwegh A. J. M., de Jong I. J., Kerver E. D., van Tinteren H. and Bergman A. M. (20140710). Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. : Cancer.

MLA

Badrising Sushil, van der Noort Vincent, van Oort Inge M, van den Berg H Pieter, Los Maartje, Hamberg Paul, Coenen Jules L, van den Eertwegh Alfons J M, de Jong Igle J, Kerver Emile D, van Tinteren Harm and Bergman Andries M. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. : Cancer. 20140710.